Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186: 222-226

Stellenbosch University, Johannesburg, Gauteng, South Africa
The British Journal of Psychiatry (Impact Factor: 7.99). 04/2005; 186(3):222-6. DOI: 10.1192/bjp.186.3.222
Source: PubMed


Selective serotonin reuptake inhibitors are effective in the treatment of social anxiety disorder and are currently regarded as the pharmacotherapy of choice.
To investigate the efficacy and tolerability of escitalopram in the treatment of generalised social anxiety disorder.
Patients with generalised social anxiety disorder were randomised to receive placebo (n=177) or 10-20 mg escitalopram (n=181) in a 12-week, double-blind trial. The primary outcome measure was the mean change from baseline to last assessment in the Liebowitz Social Anxiety Scale (LSAS) total score.
The study showed a statistically superior therapeutic effect for escitalopram compared with placebo on the LSAS total score (P=0.005). There were significantly more responders to treatment for escitalopram than for placebo (54% v. 39%; P<0.01). The clinical relevance of these findings was supported by significant reduction in the work and social components of the Sheehan Disability Scale and by the good tolerability of escitalopram treatment.
Escitalopram was efficacious and well tolerated in the treatment of generalised social anxiety disorder.

Download full-text


Available from: Dan J. Stein, Jun 23, 2014
  • Source
    • "The scale comprises 24 social situations that are each rated for level of fear (0 = none to 3 = severe) and avoidance (0 = none to 3 = usually). We used the LSAS Total score corresponding to the calculated sum of total fear and total avoidance scores (Stein et al., 1998; Kasper et al., 2005). All participants had normal or corrected-to-normal vision and provided written informed consent prior to the experiment, which was approved by the local Ethics "
    [Show abstract] [Hide abstract]
    ABSTRACT: Defined by a persistent fear of embarrassment or negative evaluation while engaged in social interaction or public performance, social anxiety disorder (SAD) is one of the most common psychiatric syndromes. Previous research has made a considerable effort to better understand and assess this mental disorder. However, little attention has been paid to social motor behavior of patients with SAD despite its crucial importance in daily social interactions. Previous research has shown that the coordination of arm, head or postural movements of interacting people can reflect their mental states or feelings such as social connectedness and social motives, suggesting that interpersonal movement coordination may be impaired in patients suffering from SAD. The current study was specifically aimed at determining whether SAD affects the dynamics of social motor coordination. We compared the unintentional and intentional rhythmic coordination of a SAD group (19 patients paired with control participants) with the rhythmic coordination of a control group (19 control pairs) in an interpersonal pendulum coordination task. The results demonstrated that unintentional social motor coordination was preserved with SAD while intentional coordination was impaired. More specifically, intentional coordination became impaired when patients with SAD had to lead the coordination as indicated by poorer (i.e., more variable) coordination. These differences between intentional and unintentional coordination as well as between follower and leader roles reveal an impaired coordination dynamics that is specific to SAD, and thus, opens promising research directions to better understand, assess and treat this mental disorder.
    Frontiers in Behavioral Neuroscience 02/2014; 8:29. DOI:10.3389/fnbeh.2014.00029 · 3.27 Impact Factor
  • Source
    • "Several psychiatric disorders involving PFC dysfunction (Gross and Hen, 2004), such as anxiety disorders, major depression and schizophrenia, have been associated with alterations of 5HT 1A R (Akimova et al., 2009; Savitz et al., 2009). Selective serotonin reuptake inhibitors (SSRIs) are one of the most common pharmacological treatments of anxiety disorders (Kasper et al., 2005). However, failures of SSRI treatment seems to be associated with the polymorphism of 5-HT 1A R encoding gene (Lemonde et al., 2003; Czesak et al., 2012) which might affect differently the expression of pre-versus postsynaptic 5-HT 1A R (Bortolozzi et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Several psychiatric disorders involving the prefrontal cortex (PFC) are associated with a dysfunction of 5-HT1A receptors (5-HT1AR). These receptors, located on interneurons and pyramidal neurons, may influence neuronal excitability through a regulation of the balance between excitation (E) and inhibition (I). Patch-clamp recordings in mouse cortical slices were performed to determine the modulatory role of 5-HT1AR on the excitability and the synaptic plasticity of layer 5 pyramidal neurons (L5PyNs) of the PFC. This was done by a comparison of postsynaptic currents evoked by electrical stimulation in layer 2/3 of 5-HT1AR-KO and wild-type (WT) mice. We observed that the E-I balance was significantly changed from 20% E-80% I in WT mice to 23% E-77% I in 5-HT1AR-KO mice, demonstrating that 5HT1ARs contribute to the control of the balance between excitation and inhibition. Furthermore, we show that interfering with 5HT1AR reduced the magnitude of the long term potentiation of excitation (eLTP) (induced by high frequency stimulation). In addition, we show that 5HT1ARs determine the orientation of the synaptic plasticity towards LTP or LTD or no plasticity through the modulation of NMDAR-mediated currents. Our data point out to a unique role of 5-HT1A postsynaptic receptors in PFC to adapt the functional plasticity of L5PyNs towards LTP, LTD or no plasticity. This brings a new way to intervene on neuronal networks of the PFC in anxiety disorders and schizophrenia.
    Neuropharmacology 03/2013; 71. DOI:10.1016/j.neuropharm.2013.03.003 · 5.11 Impact Factor
  • Source
    • "Anxiety disorders are among the most commonly diagnosed psychiatric disorders, with an estimated prevalence of 18% in the United States (Kessler et al, 2005). The most frequently prescribed pharmacologic agents for treating anxiety are benzodiazepines and selective serotonin reuptake inhibitors (SSRIs), which are effective for 40–80% of patients depending on the disorder and the specific study (Asnis et al, 2001; Bandelow et al, 2004; Davidson et al, 1993, 2004; Hoffman and Mathew, 2008; Jorstad-Stein and Heimberg, 2009; Kasper et al, 2005; Laakmann et al, 1998; Mitte et al, 2005; Moroz and Rosenbaum, 1999; Pull and Damsa, 2008; Stein et al, 1999; Van Ameringen et al, 2009). Clinicians are often hesitant to prescribe benzodiazepines because of concerns about long-term efficacy, side effects (including sedation and cognitive impairment), and potential risks for abuse or dependence (Cloos and Ferreira, 2009; McIntosh et al, 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Pregabalin (PGB) has shown potential as an anxiolytic for treatment of generalized and social anxiety disorder. PGB binds to voltage-dependent calcium channels, leading to upregulation of GABA inhibitory activity and reduction in the release of various neurotransmitters. Previous functional magnetic resonance imaging (fMRI) studies indicate that selective serotonin reuptake inhibitors and benzodiazepines attenuate amygdala, insula, and medial prefrontal cortex activation during anticipation and emotional processing in healthy controls. The aim of this study was to examine whether acute PGB administration would attenuate activation in these regions during emotional anticipation. In this double-blind, placebo-controlled, randomized crossover study, 16 healthy controls completed a paradigm involving anticipation of negative and positive affective images during fMRI approximately 1 h after administration of placebo, 50, or 200 mg PGB. Linear mixed model analysis revealed that PGB was associated with (1) decreases in left amygdala and anterior insula activation and (2) increases in anterior cingulate (ACC) activation, during anticipation of positive and negative stimuli. There was also a region of the anterior amygdala in which PGB dose was associated with increased activation during anticipation of negative and decreased activation during anticipation of positive stimuli. Attenuation of amygdala and insula activation during anticipatory or emotional processing may represent a common regional brain mechanism for anxiolytics across drug classes. PGB induced increases in ACC activation could be a unique effect related to top-down modulation of affective processing. These results provide further support for the viability of using pharmaco-fMRI to determine the anxiolytic potential of pharmacologic agents.
    Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 03/2011; 36(7):1466-77. DOI:10.1038/npp.2011.32 · 7.05 Impact Factor
Show more